Scientus Pharma unites research & development and full commercial production facilities into one integrated organization.
Our research operations began at the MaRS Discovery District in Toronto widely considered the preeminent life sciences hub in Canada. MaRS spearheads an optimal environment for start-up success by providing early-stage seed investing for science and tech companies looking to get to market faster. Scientus’ foundational IP was borne from a research project supported by the University Health Network (UHN) under the direction of Dr. Lakshmi Kotra (a senior scientist at UHN). Dr. Hance Clarke, the Director of Pain Services and the Director of Pain Research at UHN has pioneered our early pre-clinical and clinical research.
Once we became a Licensed Producer, we moved our scientific and research operations to our state-of-the-art innovations centre just outside of Toronto.
Scientus also owns and operates a 47,000 Sq. Ft. commercial production facility, 45 minutes from downtown Toronto with the capability to do cultivation, R&D, production, packaging and analytical testing. This facility provides a flexible pharmaceutical platform in full compliance with Health Canada’s quality and regulatory requirements.
Our production capabilities allow us to product liquids, semi-solid and solids and with respect to capsules we can sell 2 piece and single piece soft gelatin capsules. It also houses a fully equipped analytical and biological testing laboratory that allows Scientus to conduct additional internal and external research and development. We’re completing the validation of our analytical test methods to allow us to conduct Quality Control that meets Health Canada’s standards.